WuXi AppTec Co., Ltd. (603259.SS)

42,00 -0,11 (-0,26%) Alla chiusura: 03:00PM CST

WuXi AppTec Co., Ltd.

288 Fute Zhong Road
Waigaoqiao Free Trade Zone
Shanghai 200131
China
86 21 5046 1111
https://www.wuxiapptec.com

Settore/i: Healthcare
Settore: Diagnostics & Research
Impiegati a tempo pieno: 41.116

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Ge Li Ph.D.	Co-Founder, Chairman, President & CEO	41,97M	N/D	1967
Dr. Minzhang Chen Ph.D.	Co-CEO & Executive Director	10,93M	N/D	1969
Dr. Qing Yang Ph.D.	Co-CEO & Executive Director	7,59M	N/D	1969
Dr. Edward Hu M.B.A.	Vice Chairman, Global Chief Investment Officer, CEO of WuXi ATU & Head of DDSU	8,37M	N/D	1962
Ms. Ming Shi	Senior VP & CFO	N/D	N/D	1974
Mr. Zhaohui Zhang	COO of China, Executive VP & Executive Director	7,05M	N/D	1969
Mr. Yuanzhou Zhang	Joint Company Secretary	N/D	N/D	1988
Mr. Ruijia Tang	IR Director	N/D	N/D	N/D
Dr. Jingchao Dong Ph.D.	Senior VP & Head of RCS	N/D	N/D	N/D
Mr. Tao Guo Ph.D.	Senior VP and Head of RCS BD&IPM	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CNY.

Descrizione

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical testing services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.

Governance aziendale

L'ISS Governance QualityScore di WuXi AppTec Co., Ltd. al 1 giugno 2024 è 3. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 2; diritti degli azionisti: 9; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.